On June 4, 2015 Cellectis reported that pre-clinical data on its engineered allogeneic CAR T-cells will be featured in two oral presentations and one poster presentation at the European Hematology Association (EHA) (Free EHA Whitepaper) Annual Meeting (Press release, Cellectis, JUN 4, 2015, View Source [SID:1234505236]). The meeting will be held from June 11th to 14th, 2015, in Vienna, Austria.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The selected presentations are as follow:

Allogeneic adoptive immunotherapy of acute myeloid leukemia (ALM) by targeting CD123 with CAR T-Cells
Oral Presentation

Session Title: Gene therapy, cellular immunotherapy & vaccination

Presentation Time: Saturday, June 13th, 2015, 12:15pm to 12:30pm

UCART19, an Allogeneic "Off-the-Shelf" Adoptive T-Cell Immunotherapy Against CD19+ B-Cell Leukemias
Oral Presentation

Session Title: Gene therapy, cellular immunotherapy & vaccination

Presentation Time: Saturday, June 13th, 2015, 12:30pm to 12:45pm

Adoptive immunotherapy of multiple myeloma (MM) with allogeneic CAR T-Cells targeting CS1: enhancement of CAR activity through CS1 gene inactivation in effector cells
Poster Presentation

Session Title: Gene therapy, cellular immunotherapy & vaccination Presentation Time: Saturday, June 13th, 2015, 5:15pm to 6:45pm